Skip to content

Observation and research program of wannian Spring wine in the treatment of knee osteoarthritis

Observation and research program of wannian Spring wine in the treatment of knee osteoarthritis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058827
Enrollment
Unknown
Registered
2022-04-17
Start date
2022-05-15
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Treatment group:Ten thousand years aphrodisiac wine combined with losolprofen sodium gel cream
Control group:Losolprofen sodium gel cream

Sponsors

Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male or female aged 38 to 80 who meet the diagnostic criteria; 2. In line with the above Western medicine diagnosis of knee osteoarthritis, evaluation criteria for early knee osteoarthritis and Chinese medicine diagnosis criteria; 3. Able to understand the provisions of the daytime function scale and complete the assessment; 4. Agree to participate in the survey and sign a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with gastrointestinal bleeding and serious primary diseases of cardiovascular, liver, kidney and hematopoietic systems; 2. Long-term use of other drugs that affect the efficacy and safety evaluation and comprehensive treatment; 3. Gouty arthritis and other arthritic diseases, and other diseases affecting lower limb function; 4. Women who are breastfeeding, pregnant or preparing to become pregnant; 5. People who are allergic to alcohol, more than two kinds of food, drugs, pollen, etc. 6. Allergic to known components of test drugs and control drugs; 7. Patients with critical illness are difficult to accurately evaluate the effectiveness and safety of new drugs.

Design outcomes

Primary

MeasureTime frame
Lysholm score of knee joint;Visual analogue scale of pain (VAS);36-item Short-Form, SF-36;Interleukin-6;Interleukin-1 ß;Tumor necrosis factor - alpha;

Countries

China

Contacts

Public ContactZhongju Xu

Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

xuzhongju2000@163.com+86 13816885764

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026